Optibrium and Intellegens Collaborate to Apply Novel Deep Learning Methods to Drug Discovery

Published: Sep 12, 2018

Partnership combines Intellegens’ proprietary AI technology withOptibrium’s expertise in predictive modelling and compound design

CAMBRIDGE, UK, 11 September, 2018 – Optibrium, a developer of software for drug discovery, today announced it had signed a collaboration agreement with Intellegens, a company developing novel artificial intelligence (AI) software. The collaboration will provide Optibrium clients with access to advanced, proprietary deep learning methods that will extend and improve predictive models to guide the more efficient design and selection of high quality drug candidates.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. By leveraging Intellegens’ Alchemite technology, the partnership will create a “next generation” predictive modelling platform that is capable of delivering more accurate predictions and enabling better decision-making when it comes to the optimisation of compounds.

The Intellegens unique deep learning tool, Alchemite, can model multiple endpoints simultaneously, gaining more information from available data than traditional quantitative structure-activity relationship (SAR) models. Intellegens’ methods are uniquely capable of building accurate models based on the sparse and uncertain data typically available in drug discovery.

This latest collaboration with Intellegens supports Optibrium’s approach to working with the leading and most innovative providers of technology and services for drug discovery and other chemistry fields.

Dr Matthew Segall, Optibrium’s CEO, commented: “We are delighted to be working with Intellegens. Their cutting-edge, deep learning technology, already proven in the field of materials design, has shown remarkable results when applied to challenging drug discovery data in our proof-of-concept studies. These methods will deliver a step-change for our users’ ability to make confident decisions regarding their research strategy.”

Dr Gareth Conduit, Chief Technical Officer and Intellegens co-founder, said: “We are excited to accelerate the adoption and the impact of our neural network engine, Alchemite, by taking it to market in the field of drug discovery with Optibrium. The world-class predictive capabilities of Alchemite, delivered lucidly by Optibrium, will be game-changing for the drug discovery market, helping to simplify elements of the compound selection and design process.”

For further information on Optibrium or StarDrop, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

For further information on Intellegens or Alchemite, please visit www.intellegens.ai or contact info@intellegens.ai

ENDS

Notes to Editors:

For high resolution image please email sarah.jeffery@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.comTo view our privacy policy, please click here.

Media contact

Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0) 7771 730919

 

  •  

Nick Foster
Head of Commercial Operations
E-mail: nick.foster@optibrium.com
Phone: +44 (0) 1223 815900

About Optibrium Ltd.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. The company’s lead product, StarDrop, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process.

Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

For further information visit www.optibrium.com or join in discussions on improving the productivity of drug discovery at www.optibrium.com/community.

About Intellegens

Intellegens is a spin-out from the University of Cambridge that has developed a unique Artificial Intelligence (AI) method for training neural networks from incomplete data. The technique, developed in the Department of Physics, has been applied to drug discovery and material design but as the technique is generic it can be applied to many domains where there is big, incomplete data.

For more information, please visit www.intellegens.ai or contact us at info@intellegens.ai

Back to news